Mason Street Advisors’s Amedisys AMED Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-17,523
| Closed | -$5.14M | – | 73 |
|
|
2020
Q4 | $5.14M | Buy |
17,523
+146
| +0.8% | +$37.4K | 0.09% | 209 |
|
|
2020
Q3 | $4.11M | Sell |
17,377
-367
| -2% | -$83.4K | 0.08% | 232 |
|
|
2020
Q2 | $3.52M | Buy |
17,744
+588
| +3% | +$110K | 0.07% | 268 |
|
|
2020
Q1 | $3.15M | Hold |
17,156
| – | – | 0.07% | 250 |
|
|
2019
Q4 | $2.86M | Buy |
17,156
+283
| +2% | +$42.1K | 0.05% | 403 |
|
|
2019
Q3 | $2.21M | Buy |
16,873
+1,330
| +9% | +$173K | 0.05% | 506 |
|
|
2019
Q2 | $1.89M | Buy |
15,543
+53
| +0.3% | +$6.29K | 0.04% | 590 |
|
|
2019
Q1 | $1.91M | Buy |
15,490
+6,478
| +72% | +$813K | 0.04% | 613 |
|
|
2018
Q4 | $1.05M | Buy |
9,012
+428
| +5% | +$50.4K | 0.03% | 787 |
|
|
2018
Q3 | $1.07M | Buy |
8,584
+321
| +4% | +$35.4K | 0.02% | 855 |
|
|
2018
Q2 | $706K | Buy |
8,263
+344
| +4% | +$25.3K | 0.02% | 971 |
|
|
2018
Q1 | $478K | Buy |
7,919
+505
| +7% | +$28.8K | 0.01% | 1050 |
|
|
2017
Q4 | $391K | Buy |
7,414
+210
| +3% | +$11.1K | 0.01% | 1115 |
|
|
2017
Q3 | $403K | Buy |
7,204
+301
| +4% | +$15.9K | 0.01% | 1087 |
|
|
2017
Q2 | $434K | Buy |
6,903
+380
| +6% | +$22.1K | 0.01% | 1034 |
|
|
2017
Q1 | $333K | Buy |
6,523
+434
| +7% | +$20.7K | 0.01% | 1105 |
|
|
2016
Q4 | $260K | Buy |
6,089
+357
| +6% | +$15.2K | 0.01% | 1160 |
|
|
2016
Q3 | $272K | Buy |
5,732
+244
| +4% | +$12.2K | 0.01% | 1103 |
|
|
2016
Q2 | $277K | Buy |
5,488
+457
| +9% | +$23.1K | 0.01% | 1059 |
|
|
2016
Q1 | $243K | Buy |
5,031
+470
| +10% | +$18.1K | 0.01% | 1079 |
|
|
2015
Q4 | $179K | Buy |
4,561
+395
| +9% | +$15.8K | 0.01% | 1136 |
|
|
2015
Q3 | $158K | Sell |
4,166
-485
| -10% | -$20.5K | 0.01% | 1151 |
|
|
2015
Q2 | $185K | Buy |
4,651
+180
| +4% | +$5.61K | 0.01% | 1118 |
|
|
2015
Q1 | $120K | Buy |
4,471
+177
| +4% | +$4.99K | ﹤0.01% | 1248 |
|
|
2014
Q4 | $126K | Buy |
4,294
+147
| +4% | +$3.63K | ﹤0.01% | 1631 |
|
|
2014
Q3 | $84K | Buy |
4,147
+22
| +0.5% | +$424 | ﹤0.01% | 1710 |
|
|
2014
Q2 | $69K | Buy |
4,125
+161
| +4% | +$2.28K | ﹤0.01% | 1760 |
|
|
2014
Q1 | $59K | Sell |
3,964
-1,199
| -23% | -$18.5K | ﹤0.01% | 1770 |
|
|
2013
Q4 | $76K | Buy |
5,163
+432
| +9% | +$6.96K | ﹤0.01% | 1763 |
|
|
2013
Q3 | $81K | Buy |
4,731
+371
| +9% | +$5.5K | ﹤0.01% | 1583 |
|
|
2013
Q2 | $51K | Buy |
+4,360
| New | +$49.9K | ﹤0.01% | 1608 |
|
Other funds holding AMED
RP
Mason Street Advisors's AMED Position: Q1 2021 in Review
Mason Street Advisors sold out of Amedisys (AMED) in Q1 2021, closing a stake of 17,523 shares — an estimated $5.14M sold.
Mason Street Advisors first reported a position in AMED in Q2 2013 and held it in 31 quarters. The position peaked at $5.14M in Q4 2020. 388 funds tracked by Wall St. Rank hold AMED as of Q1 2021.
- Mason Street Advisors reported no remaining Amedisys position as of Q1 2021 after selling out during the quarter.
- Mason Street Advisors sold 17,523 Amedisys shares in Q1 2021, an estimated $5.14M.
- Mason Street Advisors first reported a position in Amedisys in Q2 2013 and held it in 31 quarters.
- Mason Street Advisors's Amedisys position peaked at $5.14M in Q4 2020.
- 388 funds tracked by Wall St. Rank held Amedisys as of Q1 2021.
Based on Mason Street Advisors's 13F filing for Q1 2021, filed 14 May 2021.